Meta-Analysis of Neutralizing Antibody Conversion with OnabotulinumtoxinA (BOTOX®) Across Multiple Indications: Naumann M et al.

Abstract: This meta-analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. …

Movement Disorders
Vol. 25, No. 13, 2010, pp. 2211–2218
©2010 Movement Disorder Society
Authors:
Markus Naumann, MD,   1*
Alastair Carruthers, MD,  2
Jean Carruthers, MD,  3
Sheena K. Aurora, MD,  4
Ross Zafonte, DO,  5
Susan Abu-Shakra, MD,  6
Terry Boodhoo, MS,  6
Mary Ann Miller-Messana, RN,  6
George Demos, MD,  6
Lynn James, MPH,  6
Frederick Beddingfield, MD, PhD,  6,7
Amanda VanDenburgh, PhD,  6
Mary Ann Chapman, PhD,  8
and Mitchell F. Brin, MD  6,9

 

Author Details:

1    Department of Neurology, Klinikum Augsburg Neurologische Klinik, Augsburg, Germany
2   Department of Dermatology and Skin Science, University of British Columbia, Canada
3   Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada
4   Swedish Pain and Headache Center, Seattle, Washington, USA
5   Harvard Medical School, Spaulding Rehabilitation Hospital Massachusetts General Hospital, Boston, Massachusetts, USA
6   Allergan, Inc., Irvine, California, USA
7  Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
8  Visage Communications, Mead, Washington, USA
9  Department of Neurology, University of California, Irvine, California, USA